文献速递流行病学与生物统计基础与转化研究

慢性阻塞性肺疾病

Chronic obstructive pulmonary disease.
PubMed 文献 · Lancet · 2022-05-06

本文综述慢性阻塞性肺疾病(COPD)的流行病学、病理生理、影像、诊断和治疗进展。COPD由吸入有害颗粒(尤其是烟草烟雾和污染物)引起,全生命周期风险因素日益受重视。组学和影像技术创新增进了对疾病病理生物学的理解,可能推动预防、诊断和治疗进步;近5年获批新治疗有限,但基于生物标志物策略将现有疗法靶向特定亚群取得进展;COVID-19对COPD患者造成重症风险增高及医疗中断和社会隔离的负面影响。

要点

  • COPD是全球发病、死亡和医疗资源使用的主要原因,由吸入有害颗粒(尤其烟草烟雾和污染物)引起。
  • 组学和影像技术创新增进了对COPD病理生物学的理解,可能推动预防、诊断和治疗进步。
  • 近5年获批新治疗有限,但基于生物标志物策略将现有疗法靶向特定亚群取得进展。

核心结论

  • 本文综述COPD,重点介绍流行病学、病理生理、影像、诊断和治疗方面的最新进展。

研究设计与样本

  • 本文为综述(Seminar),检索范围未在摘要中报告。

主要发现

  • COPD由吸入有害颗粒(尤其是烟草烟雾和污染物)引起,全生命周期中增加发病和进展风险的因素日益受重视。
  • 组学和影像技术创新增进了对疾病病理生物学的理解,可能推动COPD预防、诊断和治疗进步。
  • 近5年获批新治疗有限,但基于生物标志物策略将现有疗法靶向特定亚群取得进展。
  • COVID-19对COPD患者造成重症风险高于健康个体,并因医疗中断和社会隔离受到负面影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity, mortality, and health-care use worldwide. COPD is caused by exposure to inhaled noxious particles, notably tobacco smoke and pollutants. However, the broad range of factors that increase the risk of development and progression of COPD throughout the life course are increasingly being recognised. Innovations in omics and imaging techniques have provided greater insight into disease pathobiology, which might result in advances in COPD prevention, diagnosis, and treatment. Although few novel treatments have been approved for COPD in the past 5 years, advances have been made in targeting existing therapies to specific subpopulations using new biomarker-based strategies. Additionally, COVID-19 has undeniably affected individuals with COPD, who are not only at higher risk for severe disease manifestations than healthy individuals but also negatively affected by interruptions in health-care delivery and social isolation. This Seminar reviews COPD with an emphasis on recent advances in epidemiology, pathophysiology, imaging, diagnosis, and treatment.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet. 2022. PMID: 35533707. doi:10.1016/S0140-6736(22)00470-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。